2022³â ´ëÇѺҾÈÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2022-10-28±³À°ÀÏÀÚ : 2022-10-28
±³À°Àå¼Ò : ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë A¡¤C·ë
±³À°ÁÖÁ¦ :
2022³â ´ëÇѺҾÈÀÇÇÐȸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺҾÈÀÇÇÐȸ (ÀÌ»çÀåÁ¦)
´ã´çÀÚ : »ç¹«±¹
¿¬¶ôó : 031-787-7434
À̸ÞÀÏ :
benzcl500@naver.com ±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 12 ½Ã°£ 40ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í »çÀüµî·Ïºñ : [ȸ¿øÀü¹®ÀÇ 4¸¸¿ø], [ºñȸ¿øÀü¹®ÀÇ 5¸¸¿ø], [±ºÀü¹®ÀÇ,°øº¸ÀÇ,Àü°øÀÇ 3¸¸¿ø], [Æò»ýȸ¿ø¸éÁ¦] ÇöÀåµî·Ïºñ : [ȸ¿øÀü¹®ÀÇ 5¸¸¿ø], [ºñȸ¿øÀü¹®ÀÇ 6¸¸¿ø], [±ºÀü¹®ÀÇ,°øº¸ÀÇ,Àü°øÀÇ 4¸¸¿ø], [Æò»ýȸ¿ø¸éÁ¦]
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 09:30~09:50 A Machine Learning Driven Simulation Analysis of the Emotional Profiles of Depression Based on Facial Expression Dynamics ÀÌÅñÔ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 09:50~10:10 Occupational stress related to anxiety and depression of Korean employees: Moderated mediation model of burnout and grit Á¤½½¾Æ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 10:10~10:30 Electrophysiological Changes Between Patients With Suicidal Ideation and Suicide Attempts: An Event-Related Potential Study À±¼ºÈÆ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 10:30~10:50 Impact of operating infectious disease designated bed on hospital preference ÀüÁ¾¿í(¸íÁöº´¿ø)
Åä·Ð 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 10:50~11:00 ÁúÀÇÀÀ´ä ()
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 11:10~12:00 (Special lecture) »çȸºÒ¾ÈÀå¾ÖÀÇ °ú°Å, ÇöÀç ±×¸®°í ¹Ì·¡ ¿À°¼·(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 12:15~12:40 A Paradigm Shift to Recover from Depression °ÁöÀÎ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 12:40~13:05 Therapeutic advantage of Agomelatine in treating depression ÇÏÅÂÇö(¼¿ïÀÇ´ë)
Åä·Ð 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 13:05~13:15 ÁúÀÇÀÀ´ä ()
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 13:30~13:50 Medical complications associated with Post-COVID conditions ÀÌÁöÇâ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 13:50~14:10 Psychological aspect of post-COVID conditions ½É¹Î¿µ(±¹¸³Á¤½Å°Ç°¼¾ÅÍ)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 14:10~14:30 Neurobiological alterations after COVID infections ¿ÀÁöÈÆ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 14:30~14:50 Treating anxiety and depression in post-COVID conditions ÀåÁø±¸(¸íÁöº´¿ø)
Åä·Ð 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 14:50~15:00 ÁúÀÇÀÀ´ä ()
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 15:10~15:30 Up to date review of early life stress in anxiety and depression ÀüÈ«Áø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 15:30~15:50 Psychosocial aspect of early life stress À̳ªÇö(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 15:50~16:10 Neurobiological aspect of early life stress ±è¹Î°æ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 16:10~16:30 Can the early life stress be a treatment target for anxiety and depression? ±èÁö¼±(¼øõÇâÀÇ´ë)
Åä·Ð 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëA 16:30~16:40 ÁúÀÇÀÀ´ä ()
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 09:30~09:50 ¹üºÒ¾ÈÀå¾Ö Áø´Ü ü°èÀÇ ¿ª»ç À±¼®È£(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 09:50~10:10 ¹üºÒ¾ÈÀå¾Ö ¹× ºÒ¾È Ư¼ºÀÇ À¯ÀüÀû ¼ÒÀÎ ¹ÚõÀÏ(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 10:10~10:30 ¹üºÒ¾ÈÀå¾ÖÀÇ ½Å°æ¿µ»óÇÐÀû ¹ÙÀÌ¿À¸¶Ä¿ ¹®Àº¼ö(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 10:30~10:50 ¹üºÒ¾ÈÀå¾Ö Ä¡·á °¡À̵å¶óÀÎÀÇ ÃֽŠÁö°ß ¼ÁØÈ£(¿¬¼¼¿øÁÖÀÇ´ë)
Åä·Ð 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 10:50~11:00 ÁúÀÇÀÀ´ä ()
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 11:10~12:00 (Special lecture) »çȸºÒ¾ÈÀå¾ÖÀÇ °ú°Å, ÇöÀç ±×¸®°í ¹Ì·¡ ¿À°¼·(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 12:15~12:40 Management of depressive and anxiety symptoms for MDD patients in COVID-19 Era ±è¿ø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 12:40~13:05 Clinical Outcomes of Anti-depressant Therapy in Korean MDD Patients: Efficacy & Safety Data of Desvenlafaxine ¾çÁ¾Ã¶(ÀüºÏÀÇ´ë)
Åä·Ð 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 13:05~13:15 ÁúÀÇÀÀ´ä ()
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 13:30~13:50 ¿Ü»óÈĽºÆ®·¹½º Àå¾Ö ÀÎÁöÇൿġ·á, Áø·á½Ç¿¡¼ Àû¿ëÇϱâ Á¤¿µÀº(Á¦ÁÖÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 13:50~14:10 °¹ÚÀå¾Ö ÀÎÁöÇൿġ·á, Áø·á½Ç¿¡¼ Àû¿ëÇϱ⠳ë´ë¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 14:10~14:30 °øȲÀå¾Ö ÀÎÁöÇൿġ·á, Áø·á½Ç¿¡¼ Àû¿ëÇϱ⠼ȣÁØ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 14:30~14:50 »çȸºÒ¾ÈÀå¾Ö ÀÎÁöÇൿġ·á, Áø·á½Ç¿¡¼ Àû¿ëÇϱ⠹è½Â¹Î(°¡ÃµÀÇ´ë)
Åä·Ð 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 14:50~15:00 ÁúÀÇÀÀ´ä ()
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 15:10~15:30 Optimism : concepts, psychobiology, treatment implication Á¶¼ºÁØ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 15:30~15:50 Gratitude : concepts, psychology, treatment implication ÀÌÁÖ¿¬(Àü³²ÀÇ´ë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 15:50~16:10 Forrgiveness : concepts, psychobiology, treatment implication ÀÌ»óÇõ(Â÷ÀÇ°úÇдë)
±³À°½Ã°£ 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 16:10~16:30 Resilience : concepts, psychobiology, treatment implication ±è¹Î°æ(Â÷ÀÇ°úÇдë)
Åä·Ð 10-28 ¹Ð·¹´Ï¾ö ÈúÆ° ¼¿ï ±×·£µåº¼·ë ·ëC 16:30~16:40 ÁúÀÇÀÀ´ä ()